SENORES quarterly results and annual financials: sales, operating profit, OPM, net profit, EPS, balance sheet, cash flow and ratios like ROCE, with YoY and QoQ growth.
Senores Pharmaceuticals Ltd reported sales of ₹192 Cr, operating profit of ₹58 Cr (OPM 30%) and net profit of ₹37 Cr for the quarter ended Sep 2026. Figures in ₹ crore, consolidated where available.
SENORES quarterly results (₹ Cr)
Metric
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Sales
103
114
138
162
171
175
180
192
Expenses
77
95
104
112
121
128
126
135
Operating Profit
26
19
34
50
50
47
54
58
OPM
25%
17%
25%
31%
29%
27%
30%
30%
Other Income
5
12
3
5
7
18
3
9
Interest
6
5
5
6
5
8
7
9
Depreciation
4
5
6
8
8
9
10
10
Profit before tax
20
21
26
41
45
47
39
48
Tax
20%
13%
20%
26%
25%
23%
23%
23%
Net Profit
16
18
21
30
34
37
30
37
EPS in Rs
3.73
3.87
4.28
7.03
6.87
6.86
6.67
8.57
SENORES profit & loss, annual (₹ Cr)
Metric
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
TTM
Sales
14
35
215
398
633
719
Expenses
12
23
173
309
464
509
Operating Profit
2
13
42
90
168
209
OPM
14%
36%
19%
23%
27%
29%
Other Income
0
4
3
19
47
37
Interest
1
2
9
22
25
30
Depreciation
1
2
10
17
31
37
Profit before tax
1
12
25
71
159
179
Tax
13%
32%
-31%
17%
24%
-
Net Profit
1
8
33
58
122
137
EPS in Rs
1.01
8.59
10.31
12.72
25.05
28.97
Dividend Payout
0%
0%
0%
0%
0%
-
SENORES balance sheet (₹ Cr)
Metric
Mar 2024
Mar 2025
Sep 2025
Mar 2026
Sep 2026
Equity Capital
31
46
-
46
46
Reserves
174
740
-
888
957
Borrowings
258
315
-
342
417
Other Liabilities
160
126
-
328
261
Total Liabilities
622
1,227
-
1,604
1,681
Fixed Assets
235
301
-
755
851
CWIP
97
172
-
17
31
Investments
0
0
-
4
6
Other Assets
289
754
-
827
792
Total Assets
622
1,227
-
1,604
1,681
SENORES cash flows (₹ Cr)
Metric
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
Cash from Operating Activity
-10
-1
-26
-46
62
Cash from Investing Activity
-24
-48
-54
-429
-121
Cash from Financing Activity
36
46
87
573
-1
Net Cash Flow
2
-3
8
98
-60
Free Cash Flow
-21
-48
-78
-203
-203
CFO/OP
-526%
3%
-56%
-41%
45%
CFO/EBITDAShare of operating profit converting into cash: CFO (before tax) / Operating Profit